
For most pharmaceutical companies, developing a medicine for a single patient would seem like commercial madness. However, Perth biotechnology player Syngenis Labs is helping turn that conventional wisdom on its head. It has joined forces with two Western Australian medical research giants to advance treatments for children with rare genetic diseases, sometimes so rare that only one patient may need the medicine.
The company has teamed up with the WA-based Perron Institute and the Personalised Medicine Centre (PMC), a joint initiative between Perron and Murdoch University, to establish a specialised preclinical safety-testing platform for experimental RNA medicines targeting rare genetic and neurological diseases affecting the brain and spinal cord.
The new initiative aims to tackle one of drug development’s biggest hurdles – establishing whether promising laboratory discoveries are sufficiently safe to progress towards human trials – potentially opening another commercial avenue for Syngenis ahead of its proposed ASX listing.
Founded in Perth in 2020 by RNA researcher Professor Rakesh Veedu, Syngenis manufactures specialised genetic materials at its Bentley Technology Park laboratories, supplying universities, researchers, biotechnology companies and diagnostic developers.
Steering the commercial charge is managing director Thomas Hanly, who’s looking to turn Syngenis’s specialist RNA and DNA expertise into a scalable biotechnology business spanning drug discovery, manufacturing and personalised medicine.
The company’s products include custom-designed strands of DNA and RNA, known as oligonucleotides, used to investigate diseases, create genetic tests and develop experimental medicines. Some detect genetic variations, while others can interfere with biological instructions responsible for disease, potentially silencing harmful messages rather than simply treating symptoms. That makes them particularly promising for rare inherited disorders affecting only a handful of patients worldwide.
Syngenis operates three divisions: Syngenis Manufacturing - its revenue-generating DNA and RNA production business - Syngenis AI, which identifies and designs potential genetic medicines and Syngenis Ventures, which invests in biotechnology companies capable of commercialising its expertise.
With tens of thousands of Australian children living with rare diseases and many families still searching for a diagnosis, the opportunity to develop highly targeted, potentially life-changing medicines is substantial. Working alongside the Perron Institute and the Personalised Medicine Centre, we want to remove the technical, financial and infrastructure barriers that prevent promising discoveries from reaching patients.
Based at the PMC on Murdoch University’s South Street campus, the safety-testing platform will combine laboratory testing and studies in living systems to investigate experimental RNA medicines, identify potential safety problems earlier and determine which candidates warrant further investment.
PMC research fellows Dr Jessica Cale and Dr Kelly Martinovich will lead the work under the guidance of PMC Molecular Therapy Lab co-lead associate professor Dr May Aung-Htut.
By bringing safety testing closer to drug discovery, the partners hope to cut costs, reduce delays and accelerate promising treatments through early development.
Hanly believes the collaboration could help remove technical and financial barriers preventing genetic treatments from reaching patients, with the longer-term goal of making personalised medicines commercially and clinically viable for a much broader population.
Underscoring the growing promise of next-generation RNA medicines, serious financial firepower in the form of the Perron Institute is now flowing into WA’s rapidly expanding rare-disease research sector.
Established in 1982, the neuroscience heavyweight is Western Australia’s longest-established medical research institute and a significant Australian nucleic-acid research centre, with programs spanning motor neurone disease, Parkinson’s disease, other rare diseases and youth mental health.
Scientists at Perron helped pioneer gene-targeting technology using antisense oligonucleotides – specially designed molecules that intercept faulty RNA instructions – paving the way for the first US FDA-approved treatment for Duchenne muscular dystrophy. Two further treatments subsequently gained approval based on the underlying research.
Notably, Perron is also a strategic shareholder in Syngenis, while Syngenis’s founder and chief technology officer, Professor Veedu, has longstanding research ties with the institute and a deep background in personalised medicine.
Adding even more financial muscle to WA’s burgeoning rare-disease sector, the unrelated Stan Perron Charitable Foundation has committed $221 million over the next decade to establish the Rare Care Comprehensive Centre at Perth Children’s Hospital, with the PMC expected to play an important role in its Treatments and Trials Flagship program.
Separately, the PMC has also secured a $3.99 million Medical Research Future Fund grant to expand as a national facility developing antisense oligonucleotide medicines, including treatments tailored to rare genetic conditions.
While neither commitment represents funding awarded directly to Syngenis, the sheer scale of investment underlines the scientific and financial muscle gathering around personalised medicine.
Perhaps sensing a shift in the sands, a prospective customer is already waiting in the wings. Privately held Black Swan Biotech, another WA company developing RNA-based treatments for motor neurone disease, is expected to become a major user of the facility.
Personalised Medicine Centre director Professor Anthony Akkari believes the shared testing capability could shorten the journey towards clinical trials, while Perron chief executive Steve Arnott sees it as a resource for multiple research teams.
For Syngenis, however, the attraction is not just the science. The collaboration also plays neatly into its manufacturing plans.
Its existing business supplies research-grade and Good Laboratory Practice (GLP)-grade genetic materials, including specialist chemistries for experimental RNA treatments. GLP sets quality standards for laboratory studies, particularly drug safety testing, while Good Manufacturing Practice (GMP) governs controlled production of medicines and ingredients for clinical use.
Syngenis is now taking that strategy up another notch, building what it says will be Australia’s first GMP facility dedicated to clinical-grade oligonucleotide manufacturing, with regulatory approval targeted for 2027, subject to Therapeutic Goods Administration inspection and applicable licensing requirements.
Once approved, the facility could give Syngenis a foothold across the development chain, from early research and safety testing to manufacturing clinical-grade molecules for human trials.
Under its collaboration with Perron and Murdoch, Syngenis will contribute funding and manufacture GLP-grade genetic sequences for the PMC’s testing platform, with plans to supply GMP-grade material once operational.
The partners also aim to reduce Australia’s dependence on overseas drug-development facilities, building a more complete domestic pathway from laboratory discovery to clinical trials.
For Syngenis, the commercial upside could be significant, potentially opening a new revenue stream through preclinical safety-testing services while driving demand for its specialist RNA and DNA manufacturing capabilities.
And the company has another iron in the personalised medicine fire, having snapped up a one-third stake in Gene-S Dx through its investment arm, Syngenis Ventures, in September.
The business was established alongside the Perron Institute and the founders of Gene S, acquiring the original Gene S operation - now called Gene-S Dx - and its Rosa pharmacogenomics platform, which aims to help tailor medicines to patients based on their genetic profiles.
Unlike its new partnership with PMC, which aims to help develop new genetic treatments, Gene-S Dx uses patients’ genetic information to help doctors select existing medicines and doses better suited to their individual biology. Its Rosa platform includes RosaMind, a genetic test focused on mental health medications.
Syngenis also brings its chemistry and manufacturing expertise to the venture, potentially generating recurring revenue from components for Gene-S Dx’s genetic test kits.
Together, the initiatives give Syngenis a foot in both camps of personalised medicine – improving how existing medicines are prescribed and helping develop treatments that may not yet exist.
And the commercial opportunity stretches well beyond rare genetic disorders. Personalised medicine is already entering mainstream healthcare, with genetic testing helping doctors identify targeted cancer treatments and tailor prescribing decisions. As genetic technologies become cheaper, their applications could spread further into everyday medicine.
The eventual prize could be enormous. According to market forecasts published on Syngenis’ website, the global RNA therapeutics market is projected to surge from US$27 billion in 2025 to US$103 billion by 2035, representing compound annual growth of almost 14 per cent.
Closer to Syngenis’ manufacturing heartland, the global oligonucleotide synthesis market – the specialised genetic materials underpinning RNA medicine development – is forecast to grow from US$3.6 billion to US$10.9 billion by 2033, highlighting the potential demand for the company’s expanding production capabilities.
To bankroll its growth ambitions, Syngenis recently pocketed $4 million through a pre-IPO raise ahead of its proposed ASX listing, targeting growth across precision medicine, RNA therapeutics and oligonucleotide synthesis.
Armed with an established manufacturing business, a clinical-grade facility in development and expanding precision-medicine collaborations, the Perth biotech looks to be assembling the pieces of a business capable of earning its keep at multiple stages of the genetic-medicine value chain.
Its latest collaboration could help clear one of the most stubborn roadblocks between laboratory discovery and human trials, while opening another commercial avenue for the company.
And if the pieces fall into place, Syngenis could find itself helping turn some of medicine’s most challenging genetic discoveries into life-changing treatments – one patient at a time.
Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au
Get the latest news from thewest.com.au in your inbox.
Sign up for our emails